Full video transcriptClick to expand
Auto-generated transcript of @harms.peps's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00If you want to look better, hair, skin, nails, fat loss, muscle, these are the peptides that
- 0:04actually work. Save this video so you don't forget them. Number one is GHK-Cu. This is the
- 0:09glow-up peptide. It boosts collagen, improves skin tightness, reduces wrinkles, and helps your hair.
- 0:14Number two is growth hormone peptides like CJC, Nipam, or Mirelin. They build muscle,
- 0:18improves skin, recovery, and overall tightness that comes to with increased growth hormone.
- 0:22Number three is reda, the best one. Sorry to break it to you, but most people aren't big
- 0:26bone or bloated. They're just overweight. Reda is a triaginous fat loss peptide that hits fat loss
- 0:31at three different angles. People see incredible results on reda. If you run these three together
- 0:35for long enough, they will definitely improve your look in confidence and how you feel.
- 0:39And remember, this is not medical advice and is for research purposes only.
Peptide 'glow up' claims on TikTok: what the science actually supports
Quick answer
The creator recommends a three-peptide cosmetic and fat loss stack including GHK-Cu, unspecified growth hormone secretagogues, and retatrutide, none of which are FDA-approved for the outcomes described. Retatrutide has Phase 2 human trial data supporting significant weight loss (Jastreboff et al., 2023, NEJM), but it is not approved and is only available outside clinical trials through unregulated suppliers. GHK-Cu and CJC-1295/ipamorelin class peptides have limited to no controlled human evidence for the cosmetic outcomes claimed in the video.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide 'glow up' claims on TikTok: what the science actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide 'glow up' claims on TikTok: what the science actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptide 'glow up' claims on TikTok: what the science actually supports" from harms.peps. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator recommends a three-peptide cosmetic and fat loss stack including GHK-Cu, unspecified growth hormone secretagogues, and retatrutide, none of which are FDA-approved for the outcomes described.
The reason this review is not generic is the source wording and the canonical claim label "peptides have you tried any of these peps glowup research fatloss fit." In this clip, the useful excerpt is: "If you want to look better, hair, skin, nails, fat loss, muscle, these are the peptides that actually work." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial (2023), Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease (2024), and Emerging pharmacotherapies for obesity: A systematic review (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator recommends a three-peptide cosmetic and fat loss stack including GHK-Cu, unspecified growth hormone secretagogues, and retatrutide, none of which are FDA-approved for the outcomes described.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator recommends a three-peptide cosmetic and fat loss stack including GHK-Cu, unspecified growth hormone secretagogues, and retatrutide, none of which are FDA-approved for the outcomes described. Retatrutide has Phase 2 human trial data supporting significant weight loss (Jastreboff et al., 2023, NEJM), but it is not approved and is only available outside clinical trials through unregulated suppliers. GHK-Cu and CJC-1295/ipamorelin class peptides have limited to no controlled human evidence for the cosmetic outcomes claimed in the video.
- Retatrutide Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24% weight loss, but that was pharmaceutical-grade drug in a supervised trial, not grey-market peptide vials.
- GHK-Cu collagen claims have support in topical and in vitro research (Pickart and Margolina, 2018, Cosmetics), but systemic injectable human data for cosmetic outcomes is limited.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24% weight loss, but that was pharmaceutical-grade drug in a supervised trial, not grey-market peptide vials.
- GHK-Cu collagen claims have support in topical and in vitro research (Pickart and Margolina, 2018, Cosmetics), but systemic injectable human data for cosmetic outcomes is limited.
- CJC-1295 and ipamorelin were removed from the FDA's list of permissible bulk drug substances for compounding, meaning any current supplier is operating outside that regulatory framework.
- Stacking retatrutide with GH secretagogues has no published safety or efficacy data as a combination protocol.
- The 'research purposes only' disclaimer in a video recommending specific peptide combinations for cosmetic use does not reduce the real risk of viewers self-administering unregulated injectables.
- Mispronouncing or misidentifying peptide names ('Nipam,' 'Mirelin') is a red flag for shallow sourcing literacy in a creator recommending injectable compounds.
- No single peptide or stack is approved by the FDA for the cosmetic glow-up outcomes described in this video.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @harms.peps actually say?
The creator pitched three peptides as a cosmetic and body composition stack: GHK-Cu for skin, hair, and nails; growth hormone-releasing peptides (CJC, and what sounds like ipamorelin or similar) for muscle and recovery; and "reda" (almost certainly retatrutide) as a triple-mechanism fat loss peptide. The closing line, "this is not medical advice and is for research purposes only," is a common disclaimer that does not change the practical effect of the recommendations being made.
The video is light on mechanism and completely silent on dosing, sourcing, risk, or regulatory status. Claims like "they will definitely improve your look" are presented as settled fact rather than as outcomes from early-stage or preclinical research.
Does the science back this up?
Partially, and the degree varies a lot by peptide. GHK-Cu has the most published human-adjacent data. Retatrutide has legitimate Phase 2 trial data behind it. The growth hormone secretagogue claims are the weakest of the three in terms of direct cosmetic evidence.
GHK-Cu (copper tripeptide) has demonstrated collagen-stimulating and antioxidant activity in cell culture and some small human studies. Pickart and Margolina (2018, Cosmetics) reviewed its skin remodeling activity and noted consistent signals in wound healing and collagen synthesis. That said, most studies use topical application, not injectable peptide, and effect sizes in humans are modest.
Retatrutide is a GIP, GLP-1, and glucagon triple-receptor agonist currently in Phase 2 trials. Jastreboff et al. (2023, NEJM) reported up to 24% body weight reduction over 48 weeks in adults with obesity. Describing it as hitting "fat loss at three different angles" is a rough but not entirely wrong description of its tri-agonist mechanism. What the creator skips: this drug is not approved, not available as a legitimate compounded peptide, and sourced entirely from unregulated grey-market labs.
The growth hormone peptide claims are the loosest. Increased GH pulse amplitude from secretagogues does not automatically translate to the cosmetic tightness outcomes described.
What did they get wrong (or right)?
They got the broad category right on retatrutide: it does have the most impressive clinical weight loss data of any peptide currently in trials. Credit where it is due. The GHK-Cu collagen claim is also directionally accurate, though overstated for systemic injectable use versus topical.
What they got wrong is significant. "They will definitely improve your look" is not supported by any controlled evidence for this specific stack used together. Stacking a GH secretagogue with a potent tri-agonist receptor agonist is not a tested or approved combination, and presenting it as a routine optimization protocol is irresponsible.
The "not medical advice" disclaimer while naming specific compounds and outcomes is a legal fig leaf, not a genuine safety caveat. The creator also mispronounces or misnames several peptides, which raises real questions about sourcing literacy. "Nipam" and "Mirelin" do not correspond to established peptide names, suggesting either audio issues or shallow familiarity with the compounds being recommended.
What should you actually know?
Retatrutide is not approved by the FDA for any indication. It exists in commercial grey markets as an unverified research chemical, with no quality control, no established human dosing protocol, and no long-term safety data outside the closely monitored Phase 2 trial setting. The Jastreboff 2023 NEJM data is real and genuinely exciting, but it was generated in a clinical trial with strict screening, medical supervision, and standardized pharmaceutical-grade compound. What you buy from a peptide vendor is not that.
GHK-Cu has a reasonable safety profile in topical use. Systemic injectable GHK-Cu has far less human data. Injecting anything from an unregulated supplier carries contamination, sterility, and dosing risks that no disclaimer erases.
Growth hormone secretagogues like CJC-1295 and ipamorelin are not approved drugs in the US. They have been removed from the FDA's list of permissible compounded substances. Anyone selling them as compounded medications is operating outside current regulatory guidance.
- Always ask where a peptide is sourced before considering any use.
- "Research purposes only" does not make an unapproved injectable safe to self-administer.
- Phase 2 trial results for retatrutide are real, but those results came from pharmaceutical-grade drug in supervised settings, not grey-market vials.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
harms.peps · TikTok creator
21.0K views on this video
Have you tried any of these? #peps #glowup #research #fatloss #fitness
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about retatrutide phase 2 data (jastreboff et al., 2023, nejm) showed?
Retatrutide Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24% weight loss, but that was pharmaceutical-grade drug in a supervised trial, not grey-market peptide vials.
What does the video say about ghk-cu collagen claims have support in topical?
GHK-Cu collagen claims have support in topical and in vitro research (Pickart and Margolina, 2018, Cosmetics), but systemic injectable human data for cosmetic outcomes is limited.
What does the video say about cjc-1295?
CJC-1295 and ipamorelin were removed from the FDA's list of permissible bulk drug substances for compounding, meaning any current supplier is operating outside that regulatory framework.
What does the video say about stacking retatrutide with gh secretagogues has no published safety?
Stacking retatrutide with GH secretagogues has no published safety or efficacy data as a combination protocol.
What does the video say about the 'research purposes only' disclaimer in a video recommending specific?
The 'research purposes only' disclaimer in a video recommending specific peptide combinations for cosmetic use does not reduce the real risk of viewers self-administering unregulated injectables.
What does the video say about mispronouncing?
Mispronouncing or misidentifying peptide names ('Nipam,' 'Mirelin') is a red flag for shallow sourcing literacy in a creator recommending injectable compounds.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by harms.peps, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.